TEM

TEM

USD

Tempus AI Inc. Class A Common Stock

$84.490-0.565 (-0.664%)

Real-time Price

Healthcare
Health Information Services
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$85.055

High

$88.880

Low

$83.940

Volume

8.89M

Company Fundamentals

Market Cap

14.7B

Industry

Health Information Services

Country

United States

Trading Stats

Avg Volume

9.33M

Exchange

NMS

Currency

USD

52-Week Range

Low $31.36Current $84.490High $104.32

Related News

BusinessWire

Tempus to Participate in the Stifel 2025 Healthcare Conference

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim

View more
Tempus to Participate in the Stifel 2025 Healthcare Conference
Analyst Upgrades

Piper Sandler Maintains Neutral on Tempus AI, Raises Price Target to $105

Piper Sandler analyst David Westenberg maintains Tempus AI with a Neutral and raises the price target from $70 to $105.

View more
Piper Sandler Maintains Neutral on Tempus AI, Raises Price Target to $105
Analyst Upgrades

BTIG Maintains Buy on Tempus AI, Raises Price Target to $96

BTIG analyst Mark Massaro maintains Tempus AI with a Buy and raises the price target from $85 to $96.

View more
BTIG Maintains Buy on Tempus AI, Raises Price Target to $96
BusinessWire

Tempus to Report Third Quarter 2025 Financial Results on November 4

Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter of 2025 on November 4, 2025. The company will hold the

View more
Tempus to Report Third Quarter 2025 Financial Results on November 4
BusinessWire

Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical

View more
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
BusinessWire

Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency